AGGAME

HBsAgÓпÉÄÜÏûÊÅÂð

2017ÄêÅ·Ö޸β¡Ñ§»áÐû²¼µÄ¡¶ÂýÐÔHBVѬȾÖÎÀíÁÙ´²Êµ¼ùÖ¸ÄÏ¡·[2]ÖÐÌá³ö
£¬ºËÜÕ(Ëá)ÀàÒ©ÎïÖÎÁÆÂýÐÔÒÒÐ͸ÎÑ×ÀíÏëµÄÖÎÁÆÖÕµãÊÇ¡°È·Ö¤ÎªHBsAgÏûÊÅ(ÓлòÎÞ¿¹HBsѪÇåת»»)¡±
¡£ÄÇô
£¬HBsAgÓпÉÄÜÏûÊÅÂð£¿

ÎÒÃÇÏÈ¿´¿´HBsAgÔÚÒҸβ¡¶¾Ñ¬È¾ÖÐÆðµÄ×÷ÓÃ
¡£ÒҸβ¡¶¾ÊÇÒ»ÖÖÌØÊâ»á¡°×öÒ·þ¡±µÄ²¡¶¾
¡£ÔÚÒÒÐ͸ÎÑײ¡¶¾Ñ¬È¾ÕßµÄѪÇåÖÐ
£¬²¡¶¾¿ÅÁ£¿É¸ß´ï10µÄ13´Î·½¿½±´/ºÁÉý
£¬ÆäÖÐÍêÕûµÄ(³ÉÊìµÄ)ÒÒÐ͸ÎÑײ¡¶¾¿ÅÁ£½öÕ¼Íò·ÖÖ®Ò»
£¬Ö»ÓÐÉÙÊýÊǾßÓÐÈ«»ùÒòµÄ¡¢ÓÐѬȾÐԵIJ¡¶¾¿ÅÁ£
¡£Ã¿¸öÒҸβ¡¶¾Ö»ÐèÒªÔ¼100¸öHBsAg·Ö×Ó×÷ΪËüµÄÍâĤÂÑ°×
£¬¿ÉÊÇÔÚÒҸβ¡¶¾¸´ÖÆÀú³ÌÖб¬·¢µÄHBsAgµÄÊýÄ¿±È²¡¶¾×°ÅäËùÐèԼĪ¶à³öÁË10Íò¡«100Íò±¶
£¬Êý°ÙÍò¶àÓàµÄHBsAg·Ö×ÓÔÚѪҺÖÐÑ­»·
¡£HBsAg²»µ«¿ÉÒÔ×ö²¡¶¾µÄ¡°ÍâÒ¡±
£¬Ëü»¹»á×÷ÓÃÓÚÈËÌåµÄÃâÒßϸ°û
£¬Ó°Ïì»úÌåÃâÒßϵͳ
£¬×è°­ÒҸβ¡¶¾µÄɨ³ý
¡£±ðµÄ
£¬HBsAg¿É×÷ÓÃÓÚTϸ°û
£¬Ê¹ÆäʧȥɱÉ˱»HBVѬȾµÄ¸Îϸ°ûµÄÄÜÁ¦£»¶øHBsAg×÷ÓÃÓÚBϸ°û»áÓ°ÏìÒҸβ¡¶¾¿¹ÌåµÄ±¬·¢
¡£HBsAgµÄÒ»Á¬±£´æʹHBVѬȾÂýÐÔ»¯
£¬Òò´Ë
£¬HBsAgˮƽԽµÍ
£¬²¡¶¾ÔÚÌåÄڵĻù±¾¾ÍÔ½²»Àο¿
£¬É¨³ýÆðÀ´Ò²»áÏà¶ÔÈÝÒ×
¡£

¸Îϸ°ûµÄÉúÃüÖÜÆÚԼĪΪ100Ìì
£¬ÌìÌìÔ¼ÓÐ1%µÄ¸Îϸ°ûµòÍö
£¬ÐµĸÎϸ°ûÔÙÉú
£¬¶øеĸÎϸ°ûÍùÍùÊÇûÓб»ÒҸβ¡¶¾Ñ¬È¾µÄ¡°Çå½à¡±Ï¸°û
¡£ÈôÊÇÒ»Á¬Ê¹Óÿ¹²¡¶¾Ò©ÎïÒÖÖÆÒҸβ¡¶¾¸´ÖÆ
£¬¾ÉµÄ¸Îϸ°û(°üÀ¨ÕûºÏÁËHBV DNAµÄ¸Îϸ°û)Öð½¥µòÍö
£¬ÐµÄδ±»²¡¶¾Ñ¬È¾µÄ¡°Çå½à¡±¸Îϸ°ûÒ»Ö±ÔÙÉú
£¬ºã¾ÃÒ»Á¬ÏÂÈ¥
£¬HBsAgÊÇÓпÉÄÜÏûÊŵÄ
¡£

ÎÒ¹ų́ÍåµÄÒ½ÉúÔø¶Ô2121ÀýHBeAgÒõÐÔÂýÐÔHBVѬȾÕß¾ÙÐкã¾ÃµÄËæ·Ã
¡£ÕâЩ»¼ÕßÖÐ50.4%µÄÈËÔÚ28¡«75Ëêʱ´ú»á·ºÆðHBsAg×ÔÈ»ÏûÊÅ[3]
£¬ÆÊÎöÕâЩ»¼ÕßHBsAgµÄÓÐÀûÒòËØ
£¬·¢Ã÷ÒҸβ¡¶¾µÄC»ùÒòÐͱÈB»ùÒòÐ͸üÈÝÒ××Ô¾õÐÔHBsAgÏûÊÅ
¡£ÁíÍâ
£¬ÄÐÐÔ¡¢HBV DNA<2000 IU/ml ºÍHBsAg<100 IU/ml µÄ»¼Õß×Ô¾õÐÔHBsAgÏûÊŵıÈÀý½Ï¸ß[3]
¡£

ÔŲ́ÍåµÄÁíÒ»ÏîÑо¿ÖÐ
£¬1991-1992Äê¹ÒºÅÄÉÈëºã¾ÃËæ·ÃÇÒHBsAgµÈÊý¾ÝÍêÕûµÄ2946ÀýÂýÐÔÒҸβ¡¶¾Ñ¬È¾ÕßÔÚËæ·Ã48149.1ÈË-Äêʱ´ú
£¬ÀÛ»ý18%µÄ»¼ÕßHBsAgÏûÊÅ[4]
¡£ÎÒ¹úÏã¸ÛµÄÒ½Éú¶Ô775Àý·ºÆðHBeAgÏûÊŵÄHBeAgÑôÐÔÂýÐÔHBVѬȾÕßËæ·Ã1Äê¡¢5Äê¡¢10Äê¡¢15ºó¡¢20ÄêºÍ25Äê
£¬HBsAgÏûÊÅÂÊ»®·ÖΪ0.3%¡¢1.3%¡¢3.0%¡¢8.9%¡¢15.7%ºÍ23.6%[5]
¡£

´ÓÕâЩÑо¿ÖпÉÒÔ¿´³ö
£¬ÒªµÖ´ïHBsAgÏûÊÅ
£¬ÏÈÒªµÖ´ïe¿¹Ô­ÏûÊÅ¡¢ÑªÇåѧת»»ÒÔ¼°HBV DNA¸´ÖƵĺã¾ÃÒÖÖÆ
¡£

²Î¿¼ÎÄÏ×£º

[1] ÖлªÒ½Ñ§»á¸Î²¡Ñ§·Ö»á, ÖлªÒ½Ñ§»áѬȾ²¡Ñ§·Ö»á. ÂýÐÔÒÒÐ͸ÎÑ×·ÀÖÎÖ¸ÄÏ£¨2015Äê°æ£©. Öйú¸ÎÔಡÔÓÖ¾£¨µç×Ӱ棩. 2015. (3): 1-18.

[2] EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.LID - S0168-8278(17)30185-X [pii]LID - 10.1016/j.jhep.2017.03.021 [doi]. J Hepatol. 2017 .

[3] Tseng TC, Liu CJ, Chen CL, et al. Higher lifetime chance of spontaneous surface antigen loss in hepatitis B carriers with genotype C infection. Aliment Pharmacol Ther. 2015. 41(10): 949-60.

[4] Liu J, Yang HI, Lee MH, et al. Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma. Gut. 2014. 63(10): 1648-57.

[5] Fung J, Wong DK, Seto WK, Kopaniszen M, Lai CL, Yuen MF. Hepatitis B surface antigen seroclearance: Relationship to hepatitis B e-antigen seroclearance and hepatitis B e-antigen-negative hepatitis. Am J Gastroenterol. 2014. 109(11): 1764-70.